

## Dengue Virus Type 1 (DEN-1), Hawaii

### Catalog No. NR-82

Derived from ATCC® VR-1254™

**For research use only. Not for use in humans.**

#### Contributor:

ATCC®

#### Manufacturer:

BEI Resources

#### Product Description:

Virus Classification: *Flaviviridae, Flavivirus*

Species: Dengue virus type 1

Strain/Isolate: Hawaii

Original Source: Dengue virus type 1 (DEN-1), Hawaii was isolated in 1944 from the pooled serum of six patients in Hawaii.<sup>1,2</sup>

Comments: DEN-1, Hawaii was deposited to ATCC® in 1964 by Dr. Charles L. Wisseman, Jr. and used to prepare ATCC® VR-71™ in suckling mouse. ATCC® VR-71™ was transferred to the National Institute of Allergy and Infectious Diseases (NIAID). NIAID V-574-001-522 was derived from ATCC® VR-71™ in mouse brain. NIAID V-574-001-522 was transferred to ATCC® in 1997 and used to produce ATCC® VR-1254™ in mouse brain, which was used as the inoculum for NR-82. The complete genome of DEN-1, Hawaii has been sequenced (GenBank: [KM204119](https://www.ncbi.nlm.nih.gov/nuccore/KM204119)).

Dengue virus causes the most common vector-borne viral disease of humans, with over 50 million cases in tropical and subtropical regions each year.<sup>3</sup> The disease is now endemic in over 110 countries in the world, with Southeast Asia and the Western Pacific being the most seriously affected. Dengue disease is caused by one of four closely related, but antigenically distinct, serotypes (designated DEN-1 to -4).<sup>3</sup> Infections produce a spectrum of clinical illness ranging from a nonspecific viral syndrome to severe and fatal hemorrhagic disease.<sup>4,5</sup> Humans are the major host of dengue virus, with *Aedes aegypti* mosquitoes the principal vectors.

#### Material Provided:

Each vial contains approximately 1.0 mL of cell lysate and supernatant from *Chlorocebus* (formerly *Cercopithecus*) *aethiops* kidney epithelial cells infected with DEN-1, Hawaii.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

#### Packaging/Storage:

NR-82 was packaged aseptically in plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

#### Growth Conditions:

Host: *Chlorocebus* (formerly *Cercopithecus*) *aethiops* kidney epithelial cells (Vero; ATCC® CCL-81™)

Growth Medium: Eagle's Minimum Essential Medium containing Earle's Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate and 1.5 g/L of sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalent

Infection: Cells should be 80% to 100% confluent

Incubation: 11 to 14 days at 33°C and 5% CO<sub>2</sub>

Cytopathic Effect: Cell rounding and sloughing

#### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Dengue Virus Type 1, Hawaii, NR-82."

#### Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories \(BMBL\)](#), 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

#### Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

#### Use Restrictions:

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or

its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Sabin, A. B. and R. W. Schiesinger. "Production of Immunity to Dengue with Virus Modified by Propagation in Mice." Science 101 (1945): 640–642. PubMed: 17844088.
2. Sabin, A. B. "The Dengue Group of Viruses and its Family Relationships." Bacteriol. Rev. 14 (1950): 225–232. PubMed: 14772197.
3. Holmes, E. C. and S. S. Twiddy. "The Origin, Emergence and Evolutionary Genetics of Dengue Virus." Infect. Genet. Evol. 3 (2003): 19–28. PubMed: 12797969.
4. Malavige, G. N., et al. "Dengue Viral Infections." Postgrad. Med. J. 80 (2004): 588–601. PubMed: 15466994.
5. Kao, C.-L., et al. "Laboratory Diagnosis of Dengue Virus Infection: Current and Future Perspectives in Clinical Diagnosis and Public Health." J. Microbiol. Immunol. Infect. 38 (2005): 5–16. PubMed: 15692621.
6. Puri, B., et al. "Molecular Analysis of Dengue Virus Attenuation after Serial Passage in Primary Dog Kidney Cells." J. Gen. Virol. 78 (1997): 2287–2291. PubMed: 9292016.
7. Edelman, R. "Dengue Vaccines Approach the Finish Line." Clin. Infect. Dis. 45 (2007): S56–60. PubMed: 17582571.
8. Rico-Hesse, R. "Dengue Virus Evolution and Virulence Models." Clin. Infect. Dis. 44 (2007): 1462–1166. PubMed: 17479944.
9. Clyde, K., J. L. Kyle, and E. Harris. "Recent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and Pathogenesis." J. Virol. 80 (2006): 11418–11431. PubMed: 16928749.

ATCC® is a trademark of the American Type Culture Collection.

